


## Pharmaceutical Contract Development & Manufacturing Organization Industry Players Form Alliances For Greater Capability

The Business Research Company's
Pharmaceutical Contract Development &
Manufacturing Organization Market
Report 2022 – Market Size, Trends And
Forecast 2022-2026

LONDON, GREATER LONDON, UK,
February 11, 2022 /EINPresswire.com/
-- Pharmaceutical contract
development and manufacturing
organization market trends include
companies investing towards acquiring
and forming alliances with other
companies in the market. The
pharmaceutical contract development



Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

and manufacturing companies are following the trend of merger and acquisition in order to expand their global market reach to meet the client needs, to increase their production capabilities while maintaining cost efficiencies and to get access to latest technology and new services. The high levels of merger and acquisition activities are resulting in consolidation of the contract service providers. For instance, according to a PricewaterhouseCoopers report, the largest M&A activity in the contract development and manufacturing organization sector was the deal between Thermo Fisher Scientific and Patheon, where the former acquired the latter for \$7.2 billion. Also, other important acquisitions were Thermo Fisher's acquisition of Brammer Bio for \$1.7 billion in 2019 and PAG's acquisition of Acme Formulation Pvt Ltd., in 2021 for \$145 million.

Read more on the Global Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Report:

https://www.thebusinessresearchcompany.com/report/pharmaceutical-contract-developmentand-manufacturing-organization-global-market-report

The global pharmaceutical contract development and manufacturing organization market size is expected to grow from \$114.36 billion in 2021 to \$122.31 billion in 2022 at a compound annual

growth rate (CAGR) of 7%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The pharmaceutical CMO market is expected to reach \$159.94 billion in 2026 at a CAGR of 6.9%.

The pharmaceutical contract development and manufacturing organization market growth is driven by the increase in the demand for medicines across the globe. The high prevalence of diseases and the need for a longer lifespan increased the demand for medicines pushing the pharmaceutical companies to increase the production of existing drugs and raise the investment in their R&D to promote the development of new drugs. This impels the pharmaceutical companies to collaborate with contract manufacturing organizations (CMOs) as a way to lower operational costs, thus, increasing the demand in pharmaceutical contract development and manufacturing market. According to Alkermes plc, a biopharmaceutical company indicates that pharmaceutical contract manufacturing will emerge as a strategic option for many companies ranging from very large to smaller specialty pharma entities and this mostly will happen because the pharmaceuticals companies are looking for cost cutting.

Major players covered in the global pharmaceutical contract development and manufacturing organization (CMO) industry are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH., Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited, Dishman Pharmaceuticals, HAUPT Pharma AG, Kemwell Pvt. Ltd., Nipro Corp., NextPharma, Royal DSM N.V, Althea Technologies, Thermo Fisher Scientific Inc., Lonza Group Ltd, AbbVie Inc., Consort Medical plc, Almac Group, Siegfried Holding AG, Evonik Industries AG and Vetter Pharma International GMBH.

TBRC's global pharmaceutical contract development and manufacturing organization market report is segmented by type into active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, secondary packaging, by research phase into preclinical, phase I, phase II, phase IV, by end-user into big pharmaceutical companies, generic pharmaceutical companies, small and medium-sized pharmaceutical companies.

Pharmaceutical Contract Development And Manufacturing Organization (CMO) Global Market Report 2022 – By Type (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development And Manufacturing, Secondary Packaging), By Research Phase (Preclinical, Phase I, Phase II, Phase IV), By End-User (Big Pharmaceutical Companies, Generic Pharmaceutical Companies, Small And Medium-Sized Pharmaceutical Companies) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a pharmaceutical contract development and manufacturing organization (CMO) market overview, pharmaceutical contract development and manufacturing organization forecast pharmaceutical contract development and manufacturing organization (CMO) market size and pharmaceutical contract development and manufacturing

organization growth for the whole market, pharmaceutical contract development and manufacturing organization (CMO) market segments, pharmaceutical contract development and manufacturing organization geographies, pharmaceutical contract development and manufacturing organization (CMO) market trends, pharmaceutical contract development and manufacturing organization (CMO) market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2825&type=smp

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Pharmaceutical Drugs Global Market Report 2022 – By Type (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report

Pharmaceutical API Manufacturing Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Contract Development Manufacturing Organizations Global Market Report 2022 – By Service (CMO, CRO), By Product (Small Molecules, Biologics), By End User (Big Pharma, Small and Midsize Pharma, Generic Pharmaceutical Companies) – Market Size, Trends, And Global Forecast 2022-2026

https://www.thebusinessresearchcompany.com/report/contract-development-manufacturingorganizations-global-market-report

## About The Business Research Company

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <a href="https://www.thebusinessresearch.company.com/about-the-business-research-company.aspx">https://www.thebusinessresearch.company.com/about-the-business-research-company.aspx</a>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <a href="https://bit.ly/3b7850r">https://bit.ly/3b7850r</a>
Twitter: <a href="https://bit.ly/3b1rmj5">https://bit.ly/3b1rmj5</a>

YouTube: <a href="https://www.youtube.com/channel/UC24">https://www.youtube.com/channel/UC24</a> fl0rV8cR5DxlCpgmyFQ

Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+ +44 20 7193 0708
info@tbrc.info

Visit us on social media:

Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/562848304

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.